Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?-Reference-Cited by-同舟云学术

Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?

Published:2023-07-05 Issue:4 Volume:189 Page:467-468
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:

Author:

Maronese Carlo Alberto¹²^ORCID,Ingram John R³^ORCID,Marzano Angelo V¹²^ORCID

Affiliation:

1. Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico , Milan , Italy

2. Department of Pathophysiology and Transplantation, Università degli Studi di Milano , Milan , Italy

3. Division of Infection and Immunity, Cardiff University , Cardiff , UK

Abstract

As the landscape for hidradenitis suppurativa (HS) medical treatment is rapidly expanding, seemingly taking the same steps that marked the evolution of psoriasis management, upcoming agents still do not appear to offer complete disease control. Better control of severe cases of HS refractory to biologic monotherapy may require investigation of pathogenesis-driven, combination regimens sooner rather than later.

Publisher

Oxford University Press (OUP)

Subject

Dermatology

Link

https://academic.oup.com/bjd/advance-article-pdf/doi/10.1093/bjd/ljad224/51043867/ljad224.pdf

Reference6 articles.

1. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials;Kimball;Lancet,2023

2. Modulation of disease-associated pathways in hidradenitis suppurativa by the Janus kinase 1 inhibitor povorcitinib: transcriptomic and proteomic analyses of two phase 2 studies;Liu;Int J Mol Sci,2023

3. Insights into hidradenitis suppurativa;van Straalen;J Allergy Clin Immunol,2022

4. Successful treatment of hidradenitis suppurativa and Crohn’s disease with combined guselkumab and apremilast;Agud-Dios;Dermatol Ther,2022

5. Oral surveillance and JAK inhibitor safety: the theory of relativity;Winthrop;Nat Rev Rheumatol,2022

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Hidradenitis Suppurativa Pathogenesis and Therapies from the Symposium on HS Advances 2023;Journal of Investigative Dermatology;2024-08

2. Inflammasomes: emerging therapeutic targets in hidradenitis suppurativa?;British Journal of Dermatology;2024-06-24

3. Hidradenitis Suppurativa-Related Autoinflammatory Syndromes;Dermatologic Clinics;2024-04

4. Initial steps towards developing a predictive algorithm of disease progression for hidradenitis suppurativa (HS): results from a Cox proportional hazard regression analysis on disease progression among a cohort of 335 Danish patients with HS;British Journal of Dermatology;2024-01-03

5. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study;Clinical, Cosmetic and Investigational Dermatology;2024-01